TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01380223
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 8 hr
Study: NCT01859923
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Study: NCT03787186
Drug: GLPG1690 film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of GLPG1690
Study: NCT03787186
Drug: [14C]-GLPG1690 solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 15-minute IV infusion \[14C\]-GLPG1690
Study: NCT03787186
Drug: [14C]-GLPG1690 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of \[14C\]-GLPG1690
Study: NCT00325455
Drug: MK0859
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00764361
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
Study: NCT00764361
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel applied topically to the wound once daily for 20 weeks
Study: NCT04306354
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
Study: NCT00082498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group 1 will receive placebo.
Study: NCT00003516
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Study: NCT01184664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline + placebo patch
Study: NCT01811706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally every 12 hours, for a 4 week period.
Study: NCT02763033
Drug: Bob's Red Mill®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bone marrow transplant (BMT) diet + potato-based starch
Study: NCT03435003
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
Study: NCT02087748
Drug: 1% diclofenac sodium gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
Study: NCT02087748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel 4gm applied topically Q6 hour for 48 hours
Study: NCT01103245
Drug: Spironolactone (SPL 25)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 25mg daily
Study: NCT00377793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01103245
Drug: Spironolactone 50 mg (SPL 50)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 50 mg daily
Study: NCT00955487
Drug: Inhaled Nitric Oxide (iNO)
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
Study: NCT02692742
Drug: Myelo001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Study: NCT02692742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Study: NCT04181255
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
Study: NCT02665065
Drug: Iomab-B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02665065
Drug: Conventional Care
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02827305
Drug: Gotukola
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of mouthwash to be rinsed for duration of 60 seconds
Study: NCT03882892
Drug: Atovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
Study: NCT03882892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matched to ezetimibe
Study: NCT01405924
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
Study: NCT00154791
Drug: 5-FU/LV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01557023
Drug: barrier methods
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02506257
Drug: 0.04% PHMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study: NCT02506257
Drug: 0.06% PHMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study: NCT02506257
Drug: 0.08% PHMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study: NCT01924767
Drug: BI 10773 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po taken fasting with 240 mL water
Study: NCT04466904
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated by subcutaneous injection
Study: NCT04466904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated by subcutaneous injection
Study: NCT03479736
Drug: Other Antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
Study: NCT00653341
Drug: NPH human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00101686
Drug: Oral Capecitabine with Irinotecan
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
Study: NCT00348439
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
Study: NCT01664910
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01436071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder delivered by Novel Dry Powder Inhaler
Study: NCT00584168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
Study: NCT02950948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
Study: NCT00973453
Drug: PURETHAL Mites 20,000 AUeq/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study: NCT00973453
Drug: PURETHAL Mites 20,000 AUeq/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study: NCT00973453
Drug: PURETHAL Mites 20,000 AUeq/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study: NCT03460756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01054456
Drug: palonesetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose administered intravenously 30 minutes pre-chemotherapy
Study: NCT02874430
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04438694
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care drugs administered as per Cairo University ICU protocol
Study: NCT03030248
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
Study: NCT00752050
Drug: Preservative-free Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Study: NCT00750724
Drug: normal saline,2 ml., intraarticular weekly for 5 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03018236
Drug: Alcohol N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
Study: NCT03522467
Drug: MRCP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
Study: NCT01135680
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
Study: NCT03018236
Drug: Alcohol Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
Study: NCT03018236
Drug: Cocaine N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
Study: NCT01135680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
Study: NCT00889499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHCL 0,9%
Study: NCT02498288
Drug: Isotretinoin: Reference Medication 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Study: NCT02498288
Drug: Isotretinoin: Reference Medication 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Study: NCT03146065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Placebo to different doses of PF-06730512
Study: NCT01135680
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
Study: NCT02498288
Drug: Isotretinoin: Test Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
Study: NCT03563066
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
Study: NCT01623115
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Study: NCT01623115
Drug: Lipid Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT00006252
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
Study: NCT03703856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.
Study: NCT02656420
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as comparison to broccoli sprout-derived beverages
Study: NCT03873766
Drug: Intrapleural Medications
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
Study: NCT02625792
Drug: Endo-Clot(TM)
Normalized name: 2-acetoxy-1, 8-cineole, (+)-endo-
Approvals — FDA: no, EMA: no, PMDA: no
Description: After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
Study: NCT01599000
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed-dose tablet, six doses over three days, according to weight group
Study: NCT05713773
Drug: coated beads glucose (8 g) and caffeine anhydrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Study: NCT02318563
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching oral solution containing no cannabidiol
Study: NCT03788174
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT02336607
Drug: Felodipine tablet (Plendil)+Hydrochlorothiazide
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Study: NCT05713773
Drug: coated beads glucose (8 g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Study: NCT01180335
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles FEC followed by 4 cycles docetaxel
Study: NCT01527968
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
Study: NCT00903227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff of inhaled Placebo twice a day
Study: NCT00903227
Drug: Placebo intranasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intranasal spray 2 squirts each nostril once a day
Study: NCT02709655
Drug: Fluoxetine 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Study: NCT01600729
Drug: No Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention.
Study: NCT03170726
Drug: arveles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative and postoperative pain values between these three groups will be compared.
Study: NCT03170726
Drug: intrafen 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
Study: NCT00433199
Drug: Testosterone (T) Gel 1.62%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
Study: NCT00433199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control
Study: NCT01920594
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
Study: NCT01920594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
Study: NCT00679588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study: NCT01454596
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
Study: NCT02434744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed in combination
Study: NCT02869022
Drug: Custodiol-N
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Study: NCT02869022
Drug: Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Study: NCT02394314
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0382 administered subcutaneously
Study: NCT01170962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet, Oral, 0mg, Once daily, 24 weeks
Study: NCT03887650
Drug: Liposomal Bupivicaine 1.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
Study: NCT02394314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT00488488
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT03367728
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP and Rectus Sheath Block Injections of Normal Saline